-
Par Pharmaceutical Inc. v. Novartis Pharmaceuticals Corporation et al DC CAFC
- 1:14-cv-00843
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/27/2014
- Closed: 10/07/2014
- Latest Docket Entry: 06/29/2015
- PACER
- Docket updated daily
1
Plaintiff
5
Defendants
0
Accused
Products
1
Patent-in-Suit
103
Days in
Litigation
-
Par Pharmaceutical Inc. v. Novartis Pharmaceuticals Corporation et al DC CAFC
- 1:14-cv-00843
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/27/2014
- Closed: 10/07/2014
- Latest Docket Entry: 06/29/2015
- PACER
- Docket updated daily
Cause of Action
Declaratory Judgment
Patent Invalidity
Patent Non-Infringement
Patent Non-Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Par Pharmaceutical, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 13.3 mg/24 hr ANDA product13.3 mg/24 hr Rivastigmine transdermal extended release film | US 6,316,023 B1 | All Asserted Claims |
No infringement
Entry 29Entry 26 |
